Literature DB >> 3189472

Visual acuities and dark-adapted thresholds of children with Bardet-Biedl syndrome.

M J Leys1, L A Schreiner, R M Hansen, D L Mayer, A B Fulton.   

Abstract

We studied the visual acuities and dark-adapted sensitivities of 12 children with Bardet-Biedl syndrome. All except one child, who was seen only once, were tested serially. In the first decade of life, all visual acuities were within 2 octaves of normal. All but two final visual acuities obtained from patients in their second and third decades were more than 2 octaves poorer than normal. Dark-adapted sensitivities of all patients were, or became, significantly less than normal even in those patients whose period of follow-up was limited to the first decade of life. Of the 11 patients measured serially, seven showed decreases in dark-adapted sensitivities of at least 0.5 log unit during the follow-up period, and the last measured sensitivities of all patients were at least 2 log units less than the normal mean.

Entities:  

Mesh:

Year:  1988        PMID: 3189472     DOI: 10.1016/0002-9394(88)90586-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Clinical pathology and retinal vascular structure in the Bardet-Biedl syndrome.

Authors:  T Bek; T Rosenberg
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

2.  Identification and functional analysis of the vision-specific BBS3 (ARL6) long isoform.

Authors:  Pamela R Pretorius; Lisa M Baye; Darryl Y Nishimura; Charles C Searby; Kevin Bugge; Baoli Yang; Robert F Mullins; Edwin M Stone; Val C Sheffield; Diane C Slusarski
Journal:  PLoS Genet       Date:  2010-03-19       Impact factor: 5.917

3.  Functional analysis of BBS3 A89V that results in non-syndromic retinal degeneration.

Authors:  Pamela R Pretorius; Mohammed A Aldahmesh; Fowzan S Alkuraya; Val C Sheffield; Diane C Slusarski
Journal:  Hum Mol Genet       Date:  2011-01-31       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.